nep solid result rais pt
alzheim day rememb -- failur victori
enhanc ship ahead holiday season
unexpect earli gift cf patient trikafta approv
hit bump turnaround higher cost drive ebitda
long-await manag transit set
first glanc
analyst certif import disclosur see
sustain growth resourc optim
nep solid result rais pt
nep post solid ebitda/cafd result asset portfolio continu perform well note compani continu
expect mead pipelin transact close would support suffici cash nep deliv annual
dividend growth without increment acquisit encourag see growth energi storag develop
project concert solar near-firm asset increas address opportun solar growth past
continu see wide avail capit renew project believ nep save genesi debt
refinanc interest rate move lower increas pt form base lower requir rate
return
sustain growth resourc optim
announc rel soft revenu compar expect abl deliv upsid ep expect
believ compani continu migrat higher growth busi strong technolog posit help
outperform choppi macro environ would expect compani activ market close sale
pp busi order augment growth also encourag see compani posit benefit
trend toward sustain notabl reduc materi packag increas particip circular economi
believ consum demand sustain product packag continu grow offer opportun share
report core ep ex-item vs street-high estim consensu fairli
wide dispers around consensu despit better consensu report share write
think mainli compani gave net financ margin guidanc prior full year
long-term guidanc would use weak aggress add posit share
trade pro forma tangibl book estim would still expect rotc trend
beyond close pend mutual omaha bank mob acquisit
alzheim day rememb -- failur victori
stun victori alzheim patient famili caregiv aducanumab success achiev first
posit pivot trial potenti disease-modifi drug could lead regulatori approv manag
provid detail explan incorrect futil analysi led prematur termin engag
emerg aftermath flaw decis compani provid clariti around addit analys lead
today excit news emerg actual posit studi favor clinic outcom correl amyloid plaqu
reduct result support subset patient engag base plan submit bla
forecast aducanumab revenu begin pt detail insid
callon provid posit pre-announc monday production/r stronger expect loe/
capital-expenditure lower expect increas estim accordingli ep increas three cent ebitda
rise estim adjust capital-expenditure reflect even spend remain confid
callon achiev previous announc capit budget spoken mani sharehold
lukewarm carrizo acquisit believ best path forward close deal hope announc
synergi play see enough vote block deal see materi governance/account concern
sway iss glass-lewi vote
enhanc ship ahead holiday season
time recommend outperform-r best buy compel larger cap valu name within
coverag upon much stronger digitally-driven busi model underli prospect steadi bottom-lin
expansiona function modest sale growth outsiz share repurchas activ earlier morn announc
begin oct nearli custom qualifi free next-day deliveri thousand item holiday season
product ship free ex larger scale item includ tv applianc effort turn
consum friendli on-line help improv underli strateg posit chain view note
compar compani free ship promot ran throughout last year holiday season begin oct
charg fee expedit deliveri
best buy move today follow grow trend larg scale oper build increasingli power distribut network
aim reduc time friction get product custom hand name amazon late-apr decis
offer free one-day ship product prime member subsequ mid-may respons
offer next day deliveri item toward later stage suppli chain
said mani time serv roadmap other look break mold tradit retail
compet effect decidedli competit omichannel environ on-line repres domest
revenu on-line order pick in-stor said believ investor still fulli embrac
improv sale earn power revamp particularli new driver compani begin
unexpect earli gift cf patient trikafta approv
fda vertex yesterday announc earli approv three-month review pdufa cystic fibrosi drug
trikafta surpris investor believ faster expect kalydeco approv three month nda
submiss approv kalydeco variou rare mutationsbas partli laboratori datahav given fda comfort
class cf medicin disclos wac price line kalydeco opco expect
upgrad guidanc look compani commentari earn call market
close us launch prepar reimburs discuss updat model meantim note
previous analyz hetmin cf patient popul avail follow trikafta approv
sale expect believ trikafta uptak beat expect howev await greater
visibl updat number stay bullish
hit bump turnaround higher cost drive ebitda revis
surpris move one impact core thesi pre-announc lower ebitda vs
our/street estim lower ebitda guidanc previous organ
growth remain strong terminix despit tough comp recent pre-announc
almost exclus cost-rel rais revenu guidanc
previous disappoint view higher cost accept given either growth relat spin-
relat somewhat transient/one-tim natur organ growth remain strong retent continu trend
higher maintain outperform rate
adjust ep y/i report exceed estimate/consensu respect
total revenu y/i compar estimate/consensu respect
us domest packag revenu revenu increas y/i segment volum grew day
defer ground grew respect growth driven us domest
intern packag revenu revenu increas y/i overal segment volum y/i
revenu per packag decreas y/i repres decreas y/i exclud fx
suppli chain freight revenu revenu decreas y/i expens manag led segment adjust
oper profit declin vs revenu declin y/i adjust oper margin expans
total adjust oper incom grew y/i just-report quarter compar estimate/
consensu respect adjust oper margin expand y/i
maintain adjust ep guidanc rang compar estimate/
consensu respect adjust free cash flow project versu previous
expect capit invest reduc year anticip color
compani et confer call dial-in confer id
long-await manag transit set
earli today perform-r armour announc jan presid patrik frisk assum
role ceo current ceo founder kevin plank shift role execut chairman brand chief
compani maintain rather subdu stanc toward prospect upon view sale growth
brand apt languish much stronger competit within broader athleisur categori kevin plank
repres visionari behind armour brand believ time investor could look favor upon
potenti season oper take helm kevin remain engag product develop
said read line interpret today news armour potenti signal compani continu
struggl least somewhat reposit effort
first glanc
report adjust ep vs opco/street adjust result exclud
goodwil charg usmm amort acquisit cost although hbr exceed
street appear relat back-end load exchang seasonality/mix bp one-tim impact
entir off-set sg see follow quarter maintain ep guidanc
impli ep opco/street overal result solid continu
produc strong result face neg sentiment group ep continu believ stock
under-valued market offer attract entri point
